{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T12:55:21Z","timestamp":1774875321488,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.jns.2006.01.012","type":"journal-article","created":{"date-parts":[[2006,3,10]],"date-time":"2006-03-10T14:50:21Z","timestamp":1142002221000},"page":"133-136","source":"Crossref","is-referenced-by-count":65,"title":["Adalimumab-associated optic neuritis"],"prefix":"10.1016","volume":"244","author":[{"given":"Jacob H.","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Van Stavern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry P.","family":"Frohman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger E.","family":"Turbin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2006.01.012_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1056\/NEJM199108153250704","article-title":"Association between tumor necrosis factor alpha and disease progression in patients with multiple sclerosis","volume":"325","author":"Sharief","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2006.01.012_bib2","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.47.6.1531","article-title":"Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2","volume":"47","author":"van Oosten","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2006.01.012_bib3","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W","article-title":"Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides","volume":"44","author":"Mohan","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jns.2006.01.012_bib4","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1212\/WNL.53.3.457","article-title":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study","volume":"53","author":"Lenercept","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2006.01.012_bib5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-140-8-200404200-00037-w4","article-title":"Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease","volume":"140","author":"Strong","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jns.2006.01.012_bib6","first-page":"985","article-title":"Retrobulbar optic neuritis associated with infliximab","volume":"120","author":"Foroozan","year":"2002","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jns.2006.01.012_bib7","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/00055735-200312000-00004","article-title":"Therapies with potential toxicity of neuro-ophthalmic interest","volume":"6","author":"Iuorno","year":"2003","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jns.2006.01.012_bib8","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/bmj.326.7389.579","article-title":"Bilateral anterior toxic optic neuropathy and the use of infliximab","volume":"326","author":"ten Tusscher","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jns.2006.01.012_bib9","unstructured":"Humira package insert."},{"key":"10.1016\/j.jns.2006.01.012_bib10","unstructured":"Abbott Laboratories, data on file."},{"key":"10.1016\/j.jns.2006.01.012_bib11","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ana.410300510","article-title":"Anti-tumor necrosis factor therapy abrogates autoimmune demyelination","volume":"30","author":"Selmaj","year":"1991","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2006.01.012_bib12","unstructured":"Remicade package insert."},{"key":"10.1016\/j.jns.2006.01.012_bib13","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X06000347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X06000347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,17]],"date-time":"2019-01-17T23:29:35Z","timestamp":1547767775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X06000347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":13,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0022510X06000347"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2006.01.012","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}